$HIMS News

HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40

B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $36

HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’

Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know

OMCL or HIMS: Which Is the Better Value Stock Right Now?

Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade)

HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners

Is Hims & Hers Health, Inc. (HIMS) a Top Weight Loss Stock After Barclays’ Target Increase?

Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Here's How Much $100 Invested In Hims & Hers Health 5 Years Ago Would Be Worth Today

Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy

HIMS Stock Slides Overnight: Insider Files Share Sale As CEO Teases Oura Wearable Integration

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Rallies With a July FDA Decision Looming

Barclays Maintains Overweight on Hims & Hers Health, Raises Price Target to $39

Hims & Hers: The Bull Case Remains Strong

Hims & Hers Health: Legal Risks Resolved With New International Growth Driver - Maintain Buy

Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note